Summary
Global Markets Direct’s, ‘Anaplastic Astrocytoma - Pipeline Review, H1 2016’, provides an overview of the Anaplastic Astrocytoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma
- The report reviews pipeline therapeutics for Anaplastic Astrocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anaplastic Astrocytoma therapeutics and enlists all their major and minor projects
- The report assesses Anaplastic Astrocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aduro BioTech, Inc.
Axelar AB
Boehringer Ingelheim GmbH
Burzynski Research Institute, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
e-Therapeutics Plc
Medicenna Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Orbus Therapeutics, Inc.
Pfizer Inc.
Tocagen Inc.
TVAX Biomedical, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Anaplastic Astrocytoma Overview 9
Therapeutics Development 10
Pipeline Products for Anaplastic Astrocytoma - Overview 10
Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 11
Anaplastic Astrocytoma - Therapeutics under Development by Companies 12
Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 13
Anaplastic Astrocytoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Anaplastic Astrocytoma - Products under Development by Companies 16
Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 17
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 18
Aduro BioTech, Inc. 18
Axelar AB 19
Boehringer Ingelheim GmbH 20
Burzynski Research Institute, Inc. 21
Cavion LLC 22
Celldex Therapeutics, Inc. 23
e-Therapeutics Plc 24
Medicenna Therapeutics, Inc. 25
Millennium Pharmaceuticals, Inc. 26
Novartis AG 27
Orbus Therapeutics, Inc. 28
Pfizer Inc. 29
Tocagen Inc. 30
TVAX Biomedical, Inc. 31
Anaplastic Astrocytoma - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ADU-623 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
afatinib dimaleate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
alisertib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Antineoplaston Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AXL-1717 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CDX-1401 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cellular Immunotherapy for Brain Tumors - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Cellular Immunotherapy for Gliomas - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Cellular Immunotherapy for Oncology - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
DNX-2401 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
eflornithine hydrochloride - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ETS-2101 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
flucytosine + TBio-01 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
irinotecan hydrochloride + TBio-02 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MDNA-55 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
mibefradil dihydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
nilotinib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
p28 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
palbociclib - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
TVI-Brain-1 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Anaplastic Astrocytoma - Recent Pipeline Updates 93
Anaplastic Astrocytoma - Dormant Projects 127
Anaplastic Astrocytoma - Discontinued Products 128
Anaplastic Astrocytoma - Product Development Milestones 129
Featured News & Press Releases 129
Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 129
Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 129
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131
List of Tables
Number of Products under Development for Anaplastic Astrocytoma, H1 2016 10
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Anaplastic Astrocytoma - Pipeline by Aduro BioTech, Inc., H1 2016 18
Anaplastic Astrocytoma - Pipeline by Axelar AB, H1 2016 19
Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 20
Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute, Inc., H1 2016 21
Anaplastic Astrocytoma - Pipeline by Cavion LLC, H1 2016 22
Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 23
Anaplastic Astrocytoma - Pipeline by e-Therapeutics Plc, H1 2016 24
Anaplastic Astrocytoma - Pipeline by Medicenna Therapeutics, Inc., H1 2016 25
Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 26
Anaplastic Astrocytoma - Pipeline by Novartis AG, H1 2016 27
Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics, Inc., H1 2016 28
Anaplastic Astrocytoma - Pipeline by Pfizer Inc., H1 2016 29
Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H1 2016 30
Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Assessment by Combination Products, H1 2016 33
Number of Products by Stage and Target, H1 2016 35
Number of Products by Stage and Mechanism of Action, H1 2016 37
Number of Products by Stage and Route of Administration, H1 2016 39
Number of Products by Stage and Molecule Type, H1 2016 41
Anaplastic Astrocytoma Therapeutics - Recent Pipeline Updates, H1 2016 93
Anaplastic Astrocytoma - Dormant Projects, H1 2016 127
Anaplastic Astrocytoma - Discontinued Products, H1 2016 128
List of Figures
Number of Products under Development for Anaplastic Astrocytoma, H1 2016 10
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 15
Assessment by Monotherapy Products, H1 2016 32
Assessment by Combination Products, H1 2016 33
Number of Products by Top 10 Targets, H1 2016 34
Number of Products by Stage and Top 10 Targets, H1 2016 34
Number of Products by Top 10 Mechanism of Actions, H1 2016 36
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 36
Number of Products by Routes of Administration, H1 2016 38
Number of Products by Stage and Routes of Administration, H1 2016 38
Number of Products by Molecule Types, H1 2016 40
Number of Products by Stage and Molecule Types, H1 2016 40
